Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The company's lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), for the treatment of non-small and small cell lung cancer. It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreatic duct; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has license agreement from the University of Pittsburgh of the Commonwealth System of Higher Education (University of Pittsburgh) multiple technologies relating to the development of a gene therapy product for both Type 1 and Type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.